GRFS - Grifols, S.A. News

Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUN

Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plas

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobu

BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a glo

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

First-quarter results were broadly in line with expectations, supported by strong growth in the Biop

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a glo

Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst

Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

Grifols Q1 Revenue €1.7 Billion Down From €1.786 Billion YoY

https://www.grifols.com/en/view-news/-/news/grifols-increases-q1-2026-revenues-by-3-3-to-1-7billion-

Aldeyra Therapeutics (NASDAQ:ALDX) and Grifols (NASDAQ:GRFS) Head to Head Comparison

Aldeyra Therapeutics (NASDAQ: ALDX - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) a

Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessio

U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market

'Grifols' Canadian License Restricted After Plasma Donor Deaths' - Bloomberg

https://www.bloomberg.com/news/articles/2026-04-02/grifols-canadian-license-restricted-after-plasma-

Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care

OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada

reuters.com

Grifols approves IPO of its US biopharma business

Healthcare company Grifols ‌said on Tuesday it ⁠has approved a U.S. initial public offering o

Grifols' Chronos-PD Study Demonstrates That Biological Changes In Individuals With Parkinson's Disea

Chronos‑PD shows that biological changes associated with Parkinson's disease (PD) can emerge up

Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with

BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a gl

Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following re

TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press

Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' Sites

WINNIPEG, Manitoba and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- What: Spokespeople from the Manit

Grifols: I'm Very Happy To Add In 2026

Grifols is a global leader in blood plasma, now rated 'BUY' with a €20/share PT and $23/share ADR ta

Diversify Wealth Management LLC Takes Position in Grifols, S.A. $GRFS

Diversify Wealth Management LLC bought a new position in Grifols, S.A. (NASDAQ: GRFS) during the und

Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript

reuters.com

Grifols doubles net profit in 2025, driven by revenues

Spanish drugmaker Grifols reported on Thursday a net profit of 402 million euros ($473.96 million) f

Grifols Expects Reaching Free Cash Flow Pre-M&A Pre-Dividends Of €500M-575M; 2027 Milestones Unchang

https://www.grifols.com/en/view-news/-/news/grifols-reports-revenues-of-eur-7524m-up-7-and-more-than

Grifols (GRFS) Expected to Announce Quarterly Earnings on Wednesday

Grifols (NASDAQ: GRFS - Get Free Report) is projected to issue its Q4 2025 results before the market

gurufocus.com

Brandes Investment Partners, LP's Strategic Moves: Progressive Corp Leads with 1.04% Portfolio Impac

Insightful Analysis of Brandes Investment Partners, LP (Trades, Portfolio)'s Fourth Quarter 2025 13F

Grifols, S.A. (NASDAQ:GRFS) Given Average Recommendation of “Hold” by Brokerages

Grifols, S.A. (NASDAQ: GRFS - Get Free Report) has been given a consensus recommendation of "Hold" b

Grifols (NASDAQ:GRFS) Shares Pass Above 200 Day Moving Average – Should You Sell?

Grifols, S.A. (NASDAQ: GRFS - Get Free Report) shares crossed above its two hundred day moving avera

Grifols, S.A. (NASDAQ:GRFS) Given Consensus Recommendation of “Hold” by Analysts

Shares of Grifols, S.A. (NASDAQ: GRFS - Get Free Report) have received a consensus rating of "Hold"

CORRECTION: JP Morgan Maintains Neutral on Grifols, Maintains $10 Price Target (Price Target Updated

CORRECTION: JP Morgan analyst Richard Vosser maintains Grifols (NASDAQ:GRFS) with a Neutral and main

JP Morgan Maintains Neutral on Grifols, Lowers Price Target to $10

JP Morgan analyst James Gordon maintains Grifols (NASDAQ:GRFS) with a Neutral and lowers the pric

Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Se

Stocks That Hit 52-Week Lows On Friday

On Friday morning, 446 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 930 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Thursday